Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT01113970

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01113970. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is a Phase I/II trial of a novel Indibulin dosing schedule for the treatment of metastatic breast cancer. Eligible patients will have measurable or non-measurable, metastatic or unresectable, locally advanced breast cancer and may have received any number of prior therapies for their disease. It is expected that the Phase I portion will enroll up to 20 patients and the Phase II portion will enroll up to 45 patients.

Study identification

NCT ID: NCT01113970
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Alaunos Therapeutics; Industry
Enrollment: 35 participants

Conditions and interventions

Conditions

Metastatic Breast Cancer

Interventions

Indibulin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 6, 2010 (Actual)
Primary completion: Sep 3, 2012 (Actual)
Completion: May 21, 2013 (Actual)
Last update posted: Oct 2, 2026

2010 – 2013

United States locations

U.S. sites: 4
U.S. states: 3
U.S. cities: 4

Facility	City	State	ZIP	Site status
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	—
The West Clinic	Memphis	Tennessee	38120	—
Evergreen Hematology Oncology	Spokane	Washington	99218	—
Northwest Cancer Specialists	Vancouver	Washington	98684	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01113970, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 2, 2026 · Synced Nov 12, 2026